WFRF:(Hemminki Otto)
Search: WFRF:(Hemminki Otto) > Progress in surviva...
- 4 of 23
- Previous record
- Next record
- To hitlist
- Hemminki, KariBiomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (author)
Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
- Article/chapterEnglish2021
Publisher, publication year, extent ...
- 2021-06-22
- Public Library of Science,2021
- electronicrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:umu-185623
- https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-185623URI
- https://doi.org/10.1371/journal.pone.0253236DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database provided by the local cancer registries. While the health care systems are largely similar in the two countries, the economic resources have been stronger in Sweden. In addition to the standard 1- and 5-year relative survival rates, we calculated the difference between these as a measure of how well survival was maintained between years 1 and 5. Relative 1- year survival rates increased almost linearly in both countries and reached 90% in Sweden and 80% in Finland. Although 5-year survival also developed favorably the difference between 1- and 5-year survival rates did not improve in Sweden suggesting that the gains in 5-year survival were entirely due to gains in 1-year survival. In Finland there was a gain in survival between years 1 and 5, but the gain in 1-years survival was the main contributor to the favorable 5-year survival. Age group specific analysis showed large survival differences, particularly among women. Towards the end of the follow-up period the differences narrowed but the disadvantage of the old patients remained in 5-year survival. The limitations of the study were lack of information on performed treatment and clinical stage in the NORDCAN database. In conclusion, the available data suggest that earlier diagnosis and surgical treatment of RCC have been the main driver of the favorable change in survival during the past 50 years. The main challenges are to reduce the age-specific survival gaps, particularly among women, and push survival gains past year 1.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
- Försti, AstaHopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany (author)
- Hemminki, AkseliCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland (author)
- Ljungberg, Börje,Professor,1949-Umeå universitet,Urologi och andrologi(Swepub:umu)bolj0001 (author)
- Hemminki, OttoCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Division of Urologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and University of Toronto, ON, Toronto, Canada (author)
- Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, GermanyHopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany (creator_code:org_t)
Related titles
- In:PLOS ONE: Public Library of Science161932-6203
Internet link
- https://doi.org/10.1371/journal.pone.0253236Fulltext
- https://umu.diva-portal.org/smash/get/diva2:1576563/FULLTEXT01.pdffulltext:print
- https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0253236&type=printable
- https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-185623
- https://doi.org/10.1371/journal.pone.0253236
- 4 of 23
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Hemminki, Kari
- Försti, Asta
- Hemminki, Akseli
- Ljungberg, Börje ...
- Hemminki, Otto
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- PLOS ONE
- By the university
- Umeå University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
